三生制药(01530.HK)特比澳新适应症申请获批

阿斯达克财经04-14

三生制药(01530.HK) 公布，公司向国家药品监督管理局提交的三生制药重组人血小板生成素注射液(特比澳)新适应症已获得批准，用于治疗儿童或青少年的持续性或慢性原发免疫性血小板减少症。特比澳是三生制药自主研制的重组人血小板生成素注射液，此前已获批成人实体瘤化疗后血小板减少症和成人原发免疫性血小板减少症适应症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-12 16:25...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2427397340?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","is_english":false,"pubTime":"2024-04-14 19:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2427397340","market":"sh","top_or_hot":-1,"title":"三生制药(01530.HK)特比澳新适应症申请获批","media":"阿斯达克财经","content":"<div>\n<p>三生制药(01530.HK) 公布，公司向国家药品监督管理局提交的三生制药重组人血小板生成素注射液(特比澳)新适应症已获得批准，用于治疗儿童或青少年的持续性或慢性原发免疫性血小板减少症。特比澳是三生制药自主研制的重组人血小板生成素注射液，此前已获批成人实体瘤化疗后血小板减少症和成人原发免疫性血小板减少症适应 症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-12 16:25...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1342055/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>三生制药(01530.HK)特比澳新适应症申请获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n三生制药(01530.HK)特比澳新适应症申请获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-14 19:44 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1342055/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>三生制药(01530.HK) 公布，公司向国家药品监督管理局提交的三生制药重组人血小板生成素注射液(特比澳)新适应症已获得批准，用于治疗儿童或青少年的持续性或慢性原发免疫性血小板减少症。特比澳是三生制药自主研制的重组人血小板生成素注射液，此前已获批成人实体瘤化疗后血小板减少症和成人原发免疫性血小板减少症适应 症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-12 16:25...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1342055/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1342055/latest-news/AAFN","article_id":"2427397340","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2427397340","pubTimestamp":1713095040,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"三生制药(01530.HK) 公布，公司向国家药品监督管理局提交的三生制药重组人血小板生成素注射液(特比澳)新适应症已获得批准，用于治疗儿童或青少年的持续性或慢性原发免疫性血小板减少症。特比澳是三生制药自主研制的重组人血小板生成素注射液，此前已获批成人实体瘤化疗后血小板减少症和成人原发免疫性血小板减少症适应 症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-12 16:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","BK1161":"生物科技","01530":"三生制药","BK1593":"医美概念股"},"translate_title":"3SBio (01530. HK) TPIAO Indication Application Approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"三生制药(01530.HK) 公布，公司向国家药品监督管理局提交的三生制药重组人血小板生成素注射液(特比澳)新适应症已获得批准，用于治疗儿童或青少年的持续性或慢性原发免疫性血小板减少症。特比澳是三生制药自主研制的重组人血小板生成素注射液，此前已获批成人实体瘤化疗后血小板减少症和成人原发免疫性血小板减少症适应 症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-12 16:25。)AASTOCKS新闻","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2427397340"}